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One of the ways to understand the many trajectories of aging is to focus on individuals who 
have, for a variety of reasons, enjoyed privileged access to health care and are therefore able 
to envisage an aging process that would not otherwise have been possible. This article is 
based on interviews conducted with men aged 53 to 77, living in a major Canadian city, who 
suffered serious heart incidents and subsequently took part in a clinical trial program involving 
the use of stem cells. As a result of their participation in this program, these men have new 
hope for the future, are able to make concrete plans and can entertain the possibility of aging 
“in good health.”
Given that a heart damaged by a 
heart attack cannot be repaired, 
because the tissue is scarred, me-
chanical devices (cardiac stents, 
bypasses) and medications (e.g., 
beta blockers) are used to keep 
the organ minimally functio-
nal. Heart transplants are a pos-
sible, although less attractive 
alternative, because of serious 
risks, including complications ari-
sing from immunosuppressive 
therapy. There is also a shortage 
of donors. Although the number 
of myocardial infarctions has di-
minished in recent years (the re-
duction has been more marked 
in Western Canada than in the 
Maritimes and Quebec), it is es-
timated that more than 500,000 
Canadians are currently living 
with heart disease, with 50,000 
new patients diagnosed each 
year1. Despite all the available 
treatment modalities, only 50% 
of patients who have suffered a 
heart attack survive five years af-
ter the event. 
Another possible solution is 
an operation using autologous 
stem cells (taken from the pa-
tient’s body) in order to re-
generate muscle tissue. This 
procedure avoids thorny ethical 
issues (strong opposition  >
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to the use of embryonic stem 
cells) and immunological pro-
blems (no immunosuppressive 
therapy is required, because the 
patient is his/her own donor). 
Unfortunately, some 100 clini-
cal trials conducted worldwide 
on the use of stem cells to treat 
cardiac patients have yielded 
mixed results. Some patients 
enjoyed improved health com-
pared to participants in the pla-
cebo cohort, while others saw no 
change. These trials have none-
theless demonstrated the safety 
of these procedures. They also 
show the tremendous potential 
of this type of medical techno-
logy, since tests on animals have 
produced positive results and 
trials on humans have been mo-
derately successful2. However, a 
recent article3 reached devasta-
ting conclusions for proponents 
of stem cell procedures. 
After analyzing a number of dis-
crepancies in publications on 
stem cell procedures to treat 
cardiac patients, the authors 
showed that the studies repor-
ting the most positive effects 
also had the highest number of 
discrepancies in their results. 
Bearing these uncertainties and 
discrepancies in mind, our article 
presents the rationales given 
by people with serious heart di-
sease for participating in experi-
mental stem cell trials.
Agreeing to tAke 
pArt in A clinicAl 
triAl
The patients in our study showed 
great confidence in medicine 
from the start of their participa-
tion in the protocol.
I really believe in it. I’m convinced 
this is the science of the future. I 
think we’ll all be able to heal our-
selves with this. Right now they’re 
working on specific diseases, but 
maybe one day they’ll be able to 
cure cancer with this. Anything’s 
possible. I believe this is just the 
beginning. (Patient 10) 
The interviews showed that most 
patients, with a few exceptions, 
were not aware of this techno-
logy before participating in the 
protocol. The patients generally 
stated they were keen to parti-
cipate, as the following account 
shows: 
I had one chance in two of get-
ting better afterwards. Those 
seemed like good odds to me. I 
made my decision as soon as he 
told me about it, without hesita-
tion. (Patient 10)
Most of the participants obtai-
ned information about the pro-
cedure from the consent form. 
none mentioned using the 
Internet. Some asked family 
members or acquaintances to 
help them decide whether or 
not to participate in the proto-
col. The daughter of one patient 
worked in the medical field and 
the neighbour of another had 
successfully participated in a si-
milar clinical trial.
The clinical researchers involved 
in the trials told us that almost 
all the patients agreed to parti-
cipate. The interviews revealed 
three reasons for this positive 
response: 1) the apparent sim-
plicity of the process; 2) the ab-
sence of ethical issues associated 
with their participation (com-
pared to embryonic stem cell 
procedures); 3) the fact that no 
foreign tissue or substance would 
be introduced into the patient’s 
body. This resolved the problem 
of immunosuppression and mi-
nimized potential concerns re-
lated to identity, contamination 
and pollution—what Waldby and 
Mitchell term transcorporeality4. 
One of the researchers inter-
viewed noted: 
. . . when the doctor is trying 
to convince a patient and says 
“No, no, that’s not a stem cell. 
A stem cell, [that’s] you, in your 
own body, in your bones, that’s 
a stem cell, and we’re going to 
take it out, and put it back into 
you.” So, after you say that, they 
will say, “No problem at all.” 
Most people would say that. 
(Researcher B, 2011)
Another motivation was the 
hope this innovative procedure 
gave to a person suffering from 
a potentially fatal disease. It was 
literally a “technology of hope”5:
So, I mean, I knew it was for 
the good, not for the bad. So I 
said, “Why not? I’m in this  >
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position right now; what do I 
have to lose?” So I said, “Yeah.” 
The next day there was an ambu-
lance downstairs and—zoom!—
they took me in. (Patient 8)
In addition, as noted in the li-
terature, the operation is wit-
hout major risks for the patient. 
Patients got the same message 
from the medical staff who re-
cruited them to participate in 
these clinical trials: 
There was no mention of any-
thing, no complication, danger 
or things like that. If there was, I 
wasn’t told. There was more po-
sitive than there was negative, 
you know. So the danger was 2% 
and the rest was 98%. I think it’s 
worth it; even 5% or 10%, it’s still 
worth it. (Patient 8)
Only some patients expressed 
doubts about the validity of this 
type of surgery. They were not 
sceptical about the procedure it-
self, but rather about the health 
care system. The following 
patient believed the hospital was 
developing a bone marrow bank, 
like certain establishments that 
run their own blood banks—but 
without patients’ consent:
They had to take a bone mar-
row sample and I thought it was 
to create a bank for themselves, 
because a lot of people are suf-
fering and need bone marrow. 
(Patient 4)
The inclusion of ongoing care in 
the research protocols, such as 
regular post-operative follow-up 
care for two years, was another 
incentive for patients to agree 
to participate in the trial before 
meeting with the medical team 
and surgeon. Their participation 
in the study would ensure long-
term follow-up care and an avai-
lability of resources in the health 
care system that is rarely seen in 
other departments, and is cer-
tainly not the norm for the gene-
ral public. This argument came 
more from loved ones and others 
who influenced the patient’s 
decision. 
“My brother said, ‘Claude, do 
it!’ You’ll get much better fol-
low-up care than if you don’t.’” 
(Patient 6)
This extensive, personalized 
care undeniably eased patients’ 
concerns. Although the partici-
pants rarely used the emergency 
services offered through the pro-
tocol, the fact that these ser-
vices were available reassured 
them and gave them a feeling 
of security, which probably in-
fluenced their post-operative 
health, regardless of whether 
or not they received a trans-
plant. Paradoxically, this enthu-
siasm contrasts with their very 
infrequent visits to hospitals and 
other health care establishments 
prior to their heart attack. 
The figure of The docTor
Many patients saw their surgeon 
as a charismatic star, a saviour 
and an expert. At the same time, 
some patients reported not 
seeing their surgeon often on 
account of his importance, status 
and many responsibilities. This 
confirmed his skill and reinforced 
patients’ confidence in his abili-
ties. Their confidence in the pro-
tocol and stem cell therapy was 
therefore linked to their faith in 
medicine and the professiona-
lism of its representatives. 
When your back is up against 
they wall and they offer you 
things . . . They’re the doc-
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mechanic, so I know if some-
thing needs to be repaired right 
away or not. But you’re the doc-
tor. You know what you’re talking 
about. I’ll just follow what you 
say. (Patient 2).
AdvAncing science
Patients’ confidence in the pro-
tocol, medicine and science in 
general was bolstered by their 
feeling that they were pioneers 
helping to advance science. 
Some patients noted that they 
were contributing to something 
bigger than themselves:
It’s a new study. I’m a firm belie-
ver in research. If people hadn’t 
done experiments with Aspirin, 
we wouldn’t be where we are to-
day. By participating, I can make 
a small contribution to this re-
search. (Patient 10)
Another patient confided that 
his participation in the clinical 
trial had been the most impor-
tant event of his life.
from indestructibi-
lity to VulnerAbility
coming To Terms wiTh The 
illness TrAjecTory
The trajectory of chronic heart 
disease starts with a heart at-
tack which, for most patients, 
came as an unexpected, unpre-
dictable shock with no warning 
signs. It marks the start of a so-
metimes painful awareness of 
another body, a “sick” body. 
That is why patients develop hy-
potheses around the possible 
causes of their heart attack. For 
example, some interviewees 
pointed to stress and “having 
too much on the go” as a major 
cause. Another patient thought 
he was “invincible” before his 
heart attack. The men in our 
sample were, for the most part, 
former casual workers, labourers 
and factory employees who were 
proud of their ability to carry out 
demanding manual work. After 
their heart attack, they found 
themselves forced to adopt an 
attitude of “care of the self,” in 
Michel Foucault’s terms6, and 
to see their body in a new light. 
The trajectory of their disease in-
volved looking back on their past 
and their attitude towards physi-
cal activity and productivity.
Using the metaphor of a ma-
chine allowed them to see their 
heart attack as a mechanical 
breakdown and the operation 
as a repair job. Machines have 
a limited life span and can stop 
working if they are not properly 
maintained.
There was no reason for my heart 
to give out. I don’t know why it 
happened. But it doesn’t bo-
ther me too much. If it wasn’t 
my heart, it would be something 
else. At a certain point, the ma-
chine just doesn’t work anymore. 
(Patient 6)
PosT-oPerATive rePorTs: Ac-
TiviTy As A sign of A regene-
rATed mAle body
Although patients knew they 
would not necessarily be get-
ting a stem cell transplant during 
their participation in the clinical 
trial, the vast majority believed 
that they had indeed been trans-
planted. The conclusion for most 
interviewees was “I feel good, 
therefore I got a transplant”:
As long as I feel good and have 
a lot of energy, I won’t lose any 
sleep over whether or not I got 
the transplant. I think I probably 
did, because you don’t feel bet-
ter just like that—unless I wanted 
so badly to get better that I really 
believed the placebo was my 
stem cells. (Patient 10)
Some patients experienced im-
proved health in the medium 
term, and felt more physically 
independent than before their 
heart attack. The following ex-
cerpt clearly illustrates how in-
tensely one patient enjoyed 
carrying out his former 
Patients’ confidence in the protocol, medicine 
and science in general was bolstered by their 
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activities:
I work 10 hours a day, every day, 
no problem. I think I feel even 
better than before my heart at-
tack. I’m not afraid of challenges 
and I stay fit. I’m still working 70 
hours a week. (Patient 10)
However, for the vast majority, 
post-operative rehabilitation in-
volved getting used to “not 
being able to do anything any-
more,” especially when the pa-
tient was used to being very 
active on the job or at home:
For me, there’s no middle ground. 
So I’ve learned to slow down, but 
sometimes when I slow down too 
much, that’s not good . . . I don’t 
do anything. (Patient 7)
Some patients became de-
pressed immediately after the 
operation because of changes in 
their lifestyle and physical capa-
bilities. One had to stop working 
in the freight transportation in-
dustry, while another found him-
self unable to open a jar of food:
I was feeling pretty depressed for 
a while. I couldn’t open a jar of 
peanut butter! I wondered what 
was going to happen. (Patient 4)
Other participants kept up their 
previous activities, but adjusted 
them according to the limitations 
of their no longer indestructible 
body. A lack of bodily aware-
ness was replaced by a search for 
balance: 
It didn’t change my pace of 
life, because I still do the same 
things. I still work just as hard as 
before, but not as fast. I’m still 
in construction. Before it would 
have taken me six hours to raise 
a platform; now it takes me three 
days. I get tired, so I sit down 
and take a break. I don’t run like I 
used to. (Patient 5)
Mowing the lawn, preparing for 
trips to the cottage or vacations 
in Florida, and doing jobs around 
the house were all stereotypically 
masculine roles: 
I still shovel the snow. I asked Dr. 
N. about it, because everyone 
was telling me not to do it any-
more.  (Patient 6)
conclusion
The accounts of the men we in-
terviewed showed huge confi-
dence in the experimental stem 
cell procedure. The authority of 
the surgeon and his team, as well 
as the apparent simplicity and 
safety of the procedure, eased 
any uncertainties associated with 
the protocol. The accounts pres-
ented a desire not only to rege-
nerate the damaged organ, but 
also to rebuild a masculine iden-
tity closely intertwined with phy-
sical activity and work.
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